Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 14, Number 2—February 2008
Research

Cost-effectiveness of Antiviral Stockpiling and Near-Patient Testing for Potential Influenza Pandemic

M. Ruby Siddiqui*Comments to Author  and W. John Edmunds*
Author affiliations: *Health Protection Agency, London, UK;

Main Article

Appendix Figure

Optimal cost-effectiveness of antiviral (AV) and test stockpiling (0–30 million units) for clinical attack rates (CARs) of 15%, 25%, and 35% under the a) 1918 and b) 1957/69 scenarios. The composite test (Test A) and a perfect test of 100% sensitivity and 100% specificity (Test B) are included. The most cost-effective strategies lie on the efficiency line.

Appendix Figure. Optimal cost-effectiveness of antiviral (AV) and test stockpiling (0–30 million units) for clinical attack rates (CARs) of 15%, 25%, and 35% under the a) 1918 and b) 1957/69 scenarios. The composite test (Test A) and a perfect test of 100% sensitivity and 100% specificity (Test B) are included. The most cost-effective strategies lie on the efficiency line.

Main Article

Page created: July 08, 2010
Page updated: July 08, 2010
Page reviewed: July 08, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external